4108.Tw
4108.TW operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.
Business. 4108.TW operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4108.TW operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating a conservative leverage position. Its liquidity position is strong, with a current ratio of 27.41, suggesting ample short-term assets to cover liabilities. However, the company's operating cash flow is negative at -39,715,000 TWD, and free cash flow is also negative at -67,353,000 TWD, indicating cash outflows from operations.
Profitability metrics show a challenging performance, with a return on equity of -3.11% and a return on assets of -2.47%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of -58,199,000 TWD, and an operating loss of -174,558,000 TWD, reflecting poor operational efficiency. Gross profit of 41,292,000 TWD is modest relative to revenue of 134,576,000 TWD, indicating margin compression.
The company's geographic and segment exposure is not explicitly detailed in the available data, but the revenue concentration suggests a single business line or regional focus. There is no indication of diversified revenue streams or international operations in the provided financials.
Looking ahead, the company's growth trajectory is uncertain. The current fiscal year outlook does not provide specific revenue growth projections, but the negative operating and net income suggest a challenging near-term environment. The company's capital expenditure of -5,870,000 TWD indicates some investment in operations, but the overall financial performance does not support aggressive expansion.
Risk factors include the company's negative cash flows and poor profitability, which could impact its ability to sustain operations without external financing. The risk assessment indicates low dilution potential, but the negative free cash flow and operating cash flow suggest potential liquidity pressures. No immediate filing-based liquidity or dilution flags were detected, but the financials highlight operational risks.
Recent events, including the latest financial filing, show a continued decline in earnings, with a last actual EPS of -1.00 TWD. There are no recent transcripts or additional filings that provide further insight into the company's strategic direction or operational changes.
- The company has a strong liquidity position with a high current ratio of 27.41, but it is experiencing negative operating and free cash flows.
- Profitability is poor, with a return on equity of -3.11% and a return on assets of -2.47%, both below industry medians.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.01.
- There is no immediate filing-based liquidity or dilution risk, but the negative cash flows and operating losses suggest potential operational challenges.
- The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4108.TW Market data — financials · 2026-05-26
- Phytohealth Corp Market data — analyst estimates · 2026-05-26